Long non-coding RNA ANRIL indicates a poor prognosis of cervical cancer and promotes carcinogenesis via PI3K/Akt pathways

Biomedicine and Pharmacotherapy

Volumn 85, Issue , 2017, Pages 511-516

  Zhang, Dongli ^a   Sun, Guixia ^a   Zhang, Hongxia ^a   Tian, Jun ^a   Li, Yanyun ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Cervical cancer; Long non coding RNA ANRIL; PI3K Akt; Prognosis

Indexed keywords

LONG UNTRANSLATED RNA; PI3K PROTEIN; PROTEIN; PROTEIN KINASE B; RNA ANRIL; UNCLASSIFIED DRUG; ANRIL LONG NON-CODING RNA, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOSS OF FUNCTION MUTATION; LYMPH NODE METASTASIS; MTT ASSAY; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR VOLUME; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; TUMOR INVASION; UTERINE CERVIX TUMOR;

CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, LONG NONCODING; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 85008153040     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.11.058     Document Type: Article

References (22)

1. [1] Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., Global cancer statistics. CA. Cancer J. Clin. 61 (2011), 69–90.
2. [2] Smith, J.S., Green, J., de Gonzalez, A.B., Appleby, P., Peto, J., Plummer, M., Franceschi, S., Beral, V., Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet 361 (2003), 1159–1167.
3. [3] Mercer, T.R., Dinger, M.E., Mattick, J.S., Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10 (2009), 155–159.
4. [4] Fatica, A., Bozzoni, I., Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 15 (2014), 7–21.
5. [5] Gibb, E.A., Brown, C.J., Lam, W.L., The functional role of long non-coding RNA in human carcinomas. Mol. Cancer, 10, 2011, 38.
6. [6] Zhang, H.M., Yang, F.Q., Chen, S.J., Che, J., Zheng, J.H., Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma. Tumour Biol. 36 (2015), 2947–2955.
7. [7] Ding, L.J., Li, Y., Wang, S.D., Wang, X.S., Fang, F., Wang, W.Y., Lv, P., Zhao, D.H., Wei, F., Qi, L., Long noncoding RNA lncCAMTA1 promotes proliferation and cancer stem cell-like properties of liver cancer by inhibiting CAMTA1. Int. J. Mol. Sci., 17, 2016.
8. [8] Pan, J., Li, X., Wu, W., Xue, M., Hou, H., Zhai, W., Chen, W., Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells. Cancer Lett. 382 (2016), 64–76.
9. [9] Kotake, Y., Nakagawa, T., Kitagawa, K., Suzuki, S., Liu, N., Kitagawa, M., Xiong, Y., Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 30 (2011), 1956–1962.
10. [10] Pasmant, E., Sabbagh, A., Vidaud, M., Bièche, I.A.N.R.I.L., a long, noncoding RNA, is an unexpected major hotspot in GWAS. FASEB J. 25 (2011), 444–448.
11. [11] Qiu, J., Wang, Y., Liu, Y., Zhang, Y., Ding, J., Hua, K., The long non-coding RNA ANRIL promotes proliferation and cell cycle progression and inhibits apoptosis and senescence in epithelial ovarian cancer. Oncotarget, 2016.
12. [12] Zhu, H., Li, X., Song, Y., Zhang, P., Xiao, Y., Xing, Y., Long non-coding RNA ANRIL is up-regulated in bladder cancer and regulates bladder cancer cell proliferation and apoptosis through the intrinsic pathway. Biochem. Biophys. Res. Commun. 467 (2015), 223–228.
13. [13] Zhang E-b Kong, R., Yin D-d You L-h Sun, M., Han, L., Xu T-p Xia, R., Yang J-s De, W., Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a miR-449a. Oncotarget 5 (2014), 2276–2292.
14. [14] Schiffman, M., Castle, P.E., Jeronimo, J., Rodriguez, A.C., Wacholder, S., Human papillomavirus and cervical cancer. Lancet 370 (2007), 890–907.
15. [15] Mercer, T.R., Mattick, J.S., Structure and function of long noncoding RNAs in epigenetic regulation. Nat. Struct. Mol. Biol. 20 (2013), 300–307.
16. [16] Wapinski, O., Chang, H.Y., Long noncoding RNAs and human disease. Trends Cell Biol. 21 (2011), 354–361.
17. [17] Gutschner, T., Diederichs, S., The hallmarks of cancer: a long non-coding RNA point of view. RNA Biol. 9 (2012), 703–719.
18. [18] Pasmant, E., Laurendeau, I., Heron, D., Vidaud, M., Vidaud, D., Bieche, I., Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res. 67 (2007), 3963–3969.
19. [19] Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., Mills, G.B., Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4 (2005), 988–1004.
20. [20] Xu, S., Sui, S., Zhang, J., Bai, N., Shi, Q., Zhang, G., Gao, S., You, Z., Zhan, C., Liu, F., Pang, D., Downregulation of long noncoding RNA MALAT1 induces epithelial-to-mesenchymal transition via the PI3K-AKT pathway in breast cancer. Int. J. Clin. Exp. Pathol. 8 (2015), 4881–4891.
21. [21] Yang, C., Li, X., Wang, Y., Zhao, L., Chen, W., Long non-coding RNA UCA1 regulated cell cycle distribution via CREB through PI3-K dependent pathway in bladder carcinoma cells. Gene 496 (2012), 8–16.
22. [22] Zhu, Y., Zhang, X., Qi, L., Cai, Y., Yang, P., Xuan, G., Jiang, Y., HULC long noncoding RNA silencing suppresses angiogenesis by regulating ESM-1 via the PI3K/Akt/mTOR signaling pathway in human gliomas. Oncotarget 7 (2016), 14429–14440.